Recent studies have demonstrated that synthetic peptides, called P17 and P144, previously characterized as inhibitors of TGF-β1 [40], could be a new possible therapy to impair colon cancer-derived liver metastasis [41, 42]. This evidence concerns the gene TGFB1 and colonic neoplasm.